A Phase 2 interventional study of Belumosudil (KD025) in Graft vs Host Disease, sponsored by Kadmon, a Sanofi Company. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-28.
Sponsored by Kadmon, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.
Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 97th largest by enrollment of the 389 interventional ones that give a count, is one of 16 that started in 2016, is one of 164 in phase 2, and was the 311th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 7+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Regenerative Ocular Immunobiologics LLC · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 18+
Sawa Ito, MD · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
454 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 145 · Phase 2 227 · Phase 3 48 · Phase 4 5
First in 1986; this study’s year is marked. 16 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 30 across the 389 interventional studies, 81 across the 43 observational. Of the 347 that completed or were terminated, 166 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 454 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kadmon, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Kadmon, a Sanofi Company is the lead sponsor of 14 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Sanofi has 2 studies filed under Graft vs Host Disease — fewer than ten, so there is no comparison to draw.
21 of the studies in Graft vs Host Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07776210Phase 3Regenerative Ocular Immunobiologics LLCStudy of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD) | 2027-03-31 |
| NCT06649201Case Comprehensive Cancer CenterVulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation | 2026-11 |
| NCT05675930Memorial Sloan Kettering Cancer CenterA Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant | 2026-12-22 |
| NCT04044365National Cancer Institute (NCI)Pediatric cGVHD Symptom Scale | 2026-12-31 |
| NCT03533816University of Kansas Medical CenterExpanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | 2027-01 |
Add all 21 to your calendar (.ics) → With an account.
Among the 454 studies in Graft vs Host Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was been conducted to evaluate the safety, tolerability, and activity of belumosudil (formerly known as KD025) in adult participants with chronic graft versus host disease (cGVHD).
Fifty four (54) participants were enrolled to receive orally administered belumosudil 200 milligrams (mg) once daily (QD), belumosudil 200 mg twice daily (BID), or belumosudil 400 mg QD.
Study drug was administered in 28-day cycles until disease progression or occurrence of unacceptable toxicity. Participants received study drug in the inpatient or outpatient setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate organ and bone marrow functions evaluated during the 14 days prior to enrollment as follows:
Adequate safety laboratory values:
Sexually active women of childbearing potential enrolled in the study must agree to use two forms of accepted methods of during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received belumosudil 200 mg orally QD in each 28-day treatment cycle until disease progression, unacceptable toxicity, or death whichever occurred first (maximum duration: 64.2 months).
Drug: Belumosudil (KD025)
Participants received belumosudil 200 mg orally BID in each 28-day treatment cycle until disease progression, unacceptable toxicity, or death whichever occurred first (maximum duration: 45.9 months).
Drug: Belumosudil (KD025)
Participants received belumosudil 400 mg orally QD in each 28-day treatment cycle until disease progression, unacceptable toxicity, or death whichever occurred first (maximum duration: 49.2 months).
Drug: Belumosudil (KD025)
Pharmaceutical form: Capsules or Tablets Route of administration: Oral
Also known as: SLx-2119, REZUROCK
Percentage of Participants With Overall Response (OR)
OR was defined as the percentage of participants with complete response (CR) or partial response (PR). The OR determination of chronic graft versus host disease (cGVHD) was based on cGVHD response assessment performed by clinicians as per the 2014 National Institutes of Health (NIH) Consensus Development Project for Clinical Trials in cGVHD criteria. CR was defined as the resolution of all manifestations in each organ or site. PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; and cGVHD progression was defined as the clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.
Time frame: From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)
Number of Participants With Treatment-emergent Adverse Events (TEAEs), and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study drug up to 28 days after the last dose of study drug). TEAEs included both SAEs and non-SAEs.
Time frame: From first dose of study drug up to 28 days after the last dose of study drug (maximum duration: up to 64.2 months)
Number of Participants With Best Overall Response (BOR)
BOR was defined as the participants with either a CR or PR or lack of response (LOR), where LOR included the response status of unchanged (LOR-U), mixed (LOR-M), or progression (LOR-P). BOR was assessed per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria. CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; LOR-M was defined as CR or PR in at least one organ accompanied by progression in another organ, LOR-U was defined as outcomes that did not meet the criteria for CR, PR, progression or mixed response, LOR-P was defined as progression in at least one organ or site without a response in any other organ or site.
Time frame: From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)
Number of Participants With Maximal Improvement From Baseline in Global Severity Rating (GSR) by Clinician-reported cGVHD Assessment
The GSR assessment was performed by asking the participants to rate their disease severity of cGVHD symptoms on a 0 to 10-point numeric rating scale, where score 0 indicated 'not at all severe cGVHD symptoms' and score 10 indicated 'most severe cGVHD symptoms possible'. The response was defined using scores from 9 organs: skin, eyes, mouth, esophagus, upper gastrointestinal (GI) track, lower GI tract, liver, lungs, and joints and fascia plus GSR. End of treatment (EOT) visit was performed within 3 days after participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. Maximal improvement from Baseline was calculated as lowest GSR score on scheduled visits minus GSR score at Baseline with possible ranges from -10 to 10. The lower the number means the better improvement in cGVHD symptoms. Only those categories in which at least 1 participant had data were reported.
Time frame: From Baseline up to end of treatment (i.e., up to 64.2 months)
Number of Participants With Maximal Improvement From Baseline in Symptom Activity by cGVHD Activity Assessment Participant Self-Report
cGVHD symptom severity was self-reported by participants. Participants were asked to rate their disease symptom severity over the last week on the following questions: skin itching at its worst, moth dryness at its worst, mouth pain at its worst, mouth sensitivity at its worst, main compliant on eyes, symptom severity on eyes. Severity rating was done on a 0 to 10-point numeric rating scare, where score 0 indicated 'not at all severe cGVHD symptoms' and score 10 indicated 'most severe cGVHD symptoms possible'. EOT visit was performed within 3 days after participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. Maximal improvement from Baseline was calculated as the lowest symptom severity score on scheduled visits minus the symptom severity score at Baseline with possible ranges from -10 to 10. The lower the number means the better improvement in cGVHD symptoms.
Time frame: From Baseline up to end of treatment (i.e., up to 64.2 months)
Failure-free Survival (FFS)
Failure-free survival was defined as the time (in months) from first dose of study drug to either the start of another new systemic treatment for cGVHD, relapse of the underlying disease or death. If no such events happened, FFS was censored by last response assessment or long term follow up assessment, whichever was the latest and available. Kaplan-Meier survival method was used for the analysis.
Time frame: From first dose of study drug to either start of another new systemic treatment for cGVHD, relapse of the underlying disease or death or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)
Change From Baseline in Corticosteroids Dose
Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.
Time frame: Baseline up to end of treatment (i.e., anytime up to 64.2 months)
Number of Participants With Change From Baseline in Calcineurin Inhibitor (CNI) Usage
Calcineurin inhibitors included systemic tacrolimus and cyclosporine. Number of participants who took CNI at Baseline and had reduction and discontinuation in CNI use as compared to Baseline during the study are reported in this outcome measure. EOT visit was performed within 3 days after the participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication.
Time frame: Baseline up to end of treatment (i.e., anytime up to 64.2 months)
Duration of Response (DOR)
The DOR was defined as the time (in weeks) from first documentation of response to the time of first documentation of deterioration from best response (e.g., CR to PR, or PR to LR). LOR included the response status of unchanged (LOR-U), mixed (LOR-M), or progression (LOR-P). Per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; LOR-M was defined as CR or PR in at least one organ accompanied by progression in another organ, LOR-U was defined as outcomes that did not meet the criteria for CR, PR, progression or mixed response, LOR-P was defined as progression in at least one organ or site without a response in any other organ or site. Kaplan-Meier was used for the analysis.
Time frame: From the date of first response until documented disease progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)
Time-to-Response (TTR)
Time-to-response was measured as the time (in weeks) from first dose of study drug to the time of first documentation of response. Response was defined as the participants achieving a PR or CR at any post-baseline response assessment. Per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site and PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site.
Time frame: From first dose of study drug treatment to the time of first documentation of response or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)
Percentage of Participants With Best Response in Each Individual Organ
Best response was defined as the percentage of participants with CR or PR. Response was assessed per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site. Organ response assessment was performed on 9 individual organs: skin, eyes, mouth, esophagus, upper gastrointestinal (GI), lower GI, liver, lungs, and joints and fascia and is reported in this outcome measure.
Time frame: From date of randomization until disease progression or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)
Overall Survival (OS)
Overall survival was defined as the time (in months) from first dose of study drug to the death due to any reason. If there was no death, OS was censored by last visit, last long-term follow-up, or study cut-off date, whichever occurred first. Kaplan-Meier survival method was used for the analysis.
Time frame: From first dose of study drug to date of death from any cause or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)
Time to Next Therapy (TTNT)
The TTNT was defined as the time (in months) from first treatment to the time of new systemic cGVHD treatment. TTNT was censored by last response assessment or long term follow up assessment, whichever was earlier. Kaplan-Meier survival method was used for the analysis.
Time frame: From time of first treatment to the time of new systemic cGVHD treatment or long term follow-up assessment, whichever occurred first (maximum duration: up to 64.2 months)
Change From Baseline in Overall Score on Lee cGvHD Symptom Scale at Specified Time Points
Lee cGVHD symptom scale, a patient-reported symptom scale used to measure symptom burden and has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0-Not at all, 1-Slightly, 2-Moderately, 3-Quite a bit, 4-Extremely, with lower values representing better outcome. Score for each subscale was normalized to a score ranged from 0 to 100, where higher score=worse symptoms. An overall Lee cGvHD score was calculated as average of these 7 subscales and it ranged from 0 to 100, where a higher score = worse symptoms. EOT visit was performed within 3 days after the participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication.
Time frame: Baseline, Day 1 of Cycles 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26, 27,28,29,30,31,32,33,34,35,36,37, 38,39,40,41,42,43,44,45,46,47,48, 49, 50,51,52,53, 54,55, 56, 57,58,59,60,61,62,63,67 and EOT (i.e., anytime up to 64.2 months)
Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Each Specified Time Points
FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.
Time frame: Baseline, Day 1 of Cycles 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27, 29,30,31,32,33,34,35,36,37,38, 39,40,41,43, 47,48,49,51,52,53, 54, 55,56, 57,58,60,61,62,63,67, EOT (i.e., anytime up to 64.2 months)
Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Each Specified Time Points
FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.
Time frame: Baseline, Day 1 of Cycles 2, 3,4, 5,6,7,8,9,10,11,12,13, 14,15,16,17,18,19,20,21,22,23,24,25,26, 27,29,30,31,32,33,34,35,36,37,38,39,40,41,43,47, 48,49, 51,52,53,54, 55, 56,57,58,60,61, 62, 63,67, EOT (i.e., anytime up to 64.2 months)
Change From Baseline in Percent Predicted Hemoglobin (HGB) Corrected Diffusing Capacity of Lung for Carbon Monoxide (DLco) at Each Specified Time Points
DLco is a measurement of the ability of the lungs to transfer gases from the air to the blood. Change from baseline in diffusing capacity of the lung for carbon monoxide (percent predicted hemoglobin level corrected) was reported for this measure. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.
Time frame: Baseline, Day 1 of Cycles 2,3,4,5,6,7,8,9,10,11,12,13, 14,15,16,17,18,19,20,21,22,23,24,25,26,27, 29,31,32,33,34,35,36,37,39,40,41,43,47,49,51,53,55, 61, 62, 63, 67, EOT (i.e., anytime up to 64.2 Months)
Change From Baseline in Percent Predicted Total Lung Capacity (TLC) at Each Specified Time Points
TLC is the volume of air in the lungs upon the maximum effort of inspiration. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.
Time frame: Baseline, Day 1 of Cycles 2,3, 4, 5,6,7, 8, 9, 10,11,12,13, 14, 15, 16, 17, 18, 19, 20,21, 22,23,24, 25, 26, 27,29, 30, 31,32, 33, 34, 35,36, 37, 38,39, 40,41,43,47, 48, 49,51,52,53, 54,55,56,57,58, 60,61,62, 63, 67, EOT (i.e., anytime up to 64.2 Months)
Change From Baseline in Percent Predicted Residual Volume (RV) at Each Specified Time Points
RV is the volume of air remaining in the lungs after maximum forceful expiration. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.
Time frame: Baseline, Day 1 of Cycles 2, 3, 4,5, 6,7, 8, 9, 10, 11,12, 13, 14,15, 16,17, 18, 19,20, 21,22,23, 24, 25, 26,27, 29, 30, 31, 32, 33,34, 35,36, 37,38, 39, 40,41, 43,47, 48, 49,51,52,53, 54, 55,56,57, 58,60,61,62,63,67, EOT (i.e., anytime up to 64.2 Months)
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Belumosudil and Its Metabolites (KD025m1 and KD025m2)
Cmax was the maximum observed plasma concentration, obtained by a non-compartmental analysis. Cmax data for Belumosudil and its metabolites KD025m1 and KD025m2 are reported in this outcome measure.
Time frame: Cycles 1 and 2: pre-dose (0 hour), 1, 2, 3, 4, 5, and 6 hours post-dose on Day 1
Pharmacokinetics: Time of the Maximum Observed Plasma Concentration (Tmax) of Belumosudil and Its Metabolites (KD025m1 and KD025m2)
Tmax was defined as time to reach maximum observed plasma concentration, obtained by a non-compartmental analysis. Tmax data for Belumosudil and its metabolites KD025m1 and KD025m2 are reported in this outcome measure.
Time frame: Cycles 1 and 2: pre-dose (0 hour), 1, 2, 3, 4, 5, and 6 hours post-dose on Day 1
Pharmacokinetics: The Area Under the Plasma Concentration Versus Time Curve From Time 0 to 6 Hours Post-dose (AUC0-6hr) of Belumosudil and Its Metabolites (KD025m1 and KD025m2)
AUC0-6hr was defined as area under the plasma concentration versus time curve from time 0 to 6 hours post-dose, obtained by a non-compartmental analysis from the concentration-time data. AUC0-6hr data for Belumosudil and its metabolites KD025m1 and KD025m2 are reported in this outcome measure.
Time frame: Cycles 1 and 2: pre-dose (0 hour), 1, 2, 3, 4, 5, and 6 hours post-dose on Day 1
The study was conducted at 7 active sites in the United States. A total of 64 participants were screened between 15 September 2016 and 08 March 2018, of which 10 participants were screen failures due to not meeting eligibility criteria.
| Milestone | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Started | 17 | 16 | 21 |
| Completed | 0 | 0 | 0 |
| Not completed | 17 | 16 | 21 |
| Withdrew: Disease progression | 5 | 11 | 8 |
| Withdrew: Withdrawal by subject | 2 | 4 | 4 |
| Withdrew: Adverse event | 2 | 0 | 1 |
| Withdrew: Investigator decision | 2 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 2 |
| Withdrew: Noncompliance to protocol | 1 | 0 | 0 |
| Withdrew: Sponsor decision | 1 | 0 | 0 |
| Withdrew: Other | 4 | 1 | 5 |
OR was defined as the percentage of participants with complete response (CR) or partial response (PR). The OR determination of chronic graft versus host disease (cGVHD) was based on cGVHD response assessment performed by clinicians as per the 2014 National Institutes of Health (NIH) Consensus Development Project for Clinical Trials in cGVHD criteria. CR was defined as the resolution of all manifestations in each organ or site. PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; and cGVHD progression was defined as the clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.
| percentage of participants | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Percentage of Participants With Overall Response (OR) | 64.7 (38.3 to 85.8) | 68.8 (41.3 to 89.0) | 57.1 (34.0 to 78.2) |
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study drug up to 28 days after the last dose of study drug). TEAEs included both SAEs and non-SAEs.
| Participants | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| TEAE | 17 | 16 | 20 |
| TESAE | 5 | 6 | 13 |
BOR was defined as the participants with either a CR or PR or lack of response (LOR), where LOR included the response status of unchanged (LOR-U), mixed (LOR-M), or progression (LOR-P). BOR was assessed per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria. CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; LOR-M was defined as CR or PR in at least one organ accompanied by progression in another organ, LOR-U was defined as outcomes that did not meet the criteria for CR, PR, progression or mixed response, LOR-P was defined as progression in at least one organ or site without a response in any other organ or site.
| Participants | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| CR | 0 | 0 | 0 |
| PR | 11 | 11 | 12 |
| LOR-U | 2 | 3 | 4 |
| LOR-M | 2 | 1 | 0 |
| LOR-P | 2 | 1 | 1 |
The GSR assessment was performed by asking the participants to rate their disease severity of cGVHD symptoms on a 0 to 10-point numeric rating scale, where score 0 indicated 'not at all severe cGVHD symptoms' and score 10 indicated 'most severe cGVHD symptoms possible'. The response was defined using scores from 9 organs: skin, eyes, mouth, esophagus, upper gastrointestinal (GI) track, lower GI tract, liver, lungs, and joints and fascia plus GSR. End of treatment (EOT) visit was performed within 3 days after participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. Maximal improvement from Baseline was calculated as lowest GSR score on scheduled visits minus GSR score at Baseline with possible ranges from -10 to 10. The lower the number means the better improvement in cGVHD symptoms. Only those categories in which at least 1 participant had data were reported.
| Participants | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| -7 | 0 | 0 | 2 |
| -6 | 0 | 2 | 0 |
| -5 | 2 | 2 | 0 |
| -4 | 2 | 0 | 3 |
| -3 | 4 | 0 | 1 |
| -2 | 2 | 4 | 4 |
| -1 | 1 | 2 | 4 |
| 0 | 5 | 4 | 3 |
| 1 | 0 | 1 | 1 |
| 3 | 0 | 1 | 0 |
| Missing | 1 | 0 | 3 |
cGVHD symptom severity was self-reported by participants. Participants were asked to rate their disease symptom severity over the last week on the following questions: skin itching at its worst, moth dryness at its worst, mouth pain at its worst, mouth sensitivity at its worst, main compliant on eyes, symptom severity on eyes. Severity rating was done on a 0 to 10-point numeric rating scare, where score 0 indicated 'not at all severe cGVHD symptoms' and score 10 indicated 'most severe cGVHD symptoms possible'. EOT visit was performed within 3 days after participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. Maximal improvement from Baseline was calculated as the lowest symptom severity score on scheduled visits minus the symptom severity score at Baseline with possible ranges from -10 to 10. The lower the number means the better improvement in cGVHD symptoms.
| Participants | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| -8 | 0 | 0 | 1 |
| -7 | 3 | 2 | 0 |
| -6 | 0 | 1 | 4 |
| -5 | 2 | 0 | 2 |
| -4 | 2 | 2 | 1 |
| -3 | 2 | 2 | 2 |
| -2 | 2 | 3 | 2 |
| -1 | 2 | 2 | 2 |
| 0 | 1 | 1 | 0 |
| 1 | 0 | 0 | 1 |
| 2 | 0 | 1 | 2 |
| 4 | 1 | 0 | 0 |
| Missing | 2 | 2 | 4 |
Failure-free survival was defined as the time (in months) from first dose of study drug to either the start of another new systemic treatment for cGVHD, relapse of the underlying disease or death. If no such events happened, FFS was censored by last response assessment or long term follow up assessment, whichever was the latest and available. Kaplan-Meier survival method was used for the analysis.
| months | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Failure-free Survival (FFS) | 10.6 (3.78 to NA) | 9.8 (4.01 to 19.02) | 9.7 (2.60 to 16.10) |
Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.
| milligrams per kilogram per day | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Change From Baseline in Corticosteroids Dose | -0.110 ± 0.101 | -0.111 ± 0.147 | -0.116 ± 0.152 |
Calcineurin inhibitors included systemic tacrolimus and cyclosporine. Number of participants who took CNI at Baseline and had reduction and discontinuation in CNI use as compared to Baseline during the study are reported in this outcome measure. EOT visit was performed within 3 days after the participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication.
| Participants | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Participants with reduction in CNI dose | 5 | 5 | 6 |
| Participants who discontinued CNI | 0 | 1 | 3 |
The DOR was defined as the time (in weeks) from first documentation of response to the time of first documentation of deterioration from best response (e.g., CR to PR, or PR to LR). LOR included the response status of unchanged (LOR-U), mixed (LOR-M), or progression (LOR-P). Per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; LOR-M was defined as CR or PR in at least one organ accompanied by progression in another organ, LOR-U was defined as outcomes that did not meet the criteria for CR, PR, progression or mixed response, LOR-P was defined as progression in at least one organ or site without a response in any other organ or site. Kaplan-Meier was used for the analysis.
| weeks | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Duration of Response (DOR) | 40.0 (8.14 to NA) | 10.9 (2.00 to 35.14) | 15.9 (4.14 to 38.14) |
Time-to-response was measured as the time (in weeks) from first dose of study drug to the time of first documentation of response. Response was defined as the participants achieving a PR or CR at any post-baseline response assessment. Per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site and PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site.
| weeks | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Time-to-Response (TTR) | 8.14 (7.9 to 26.1) | 8.14 (4.1 to 40.0) | 8.07 (4.1 to 67.0) |
Best response was defined as the percentage of participants with CR or PR. Response was assessed per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site. Organ response assessment was performed on 9 individual organs: skin, eyes, mouth, esophagus, upper gastrointestinal (GI), lower GI, liver, lungs, and joints and fascia and is reported in this outcome measure.
| percentage of participants | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Skin | 23.1 | 16.7 | 13.3 |
| Eyes | 35.7 | 36.4 | 23.5 |
| Mouth | 46.2 | 45.5 | 45.5 |
| Esophagus | 50.0 | — | 25.0 |
| Upper GI tract | 100.0 | 100.0 | 50.0 |
| Lower GI tract | 0 | 100.0 | 0 |
| Liver | — | 50.0 | — |
| Lungs | 0 | 0 | 30.0 |
| Joints and Fascia | 54.5 | 45.5 | 41.7 |
Overall survival was defined as the time (in months) from first dose of study drug to the death due to any reason. If there was no death, OS was censored by last visit, last long-term follow-up, or study cut-off date, whichever occurred first. Kaplan-Meier survival method was used for the analysis.
| months | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Overall Survival (OS) | NA (39.46 to NA) | NA (52.07 to NA) | NA (23.29 to NA) |
The TTNT was defined as the time (in months) from first treatment to the time of new systemic cGVHD treatment. TTNT was censored by last response assessment or long term follow up assessment, whichever was earlier. Kaplan-Meier survival method was used for the analysis.
| months | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Time to Next Therapy (TTNT) | 15.2 (5.22 to NA) | 9.8 (4.01 to 19.02) | 14.2 (2.66 to NA) |
Lee cGVHD symptom scale, a patient-reported symptom scale used to measure symptom burden and has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0-Not at all, 1-Slightly, 2-Moderately, 3-Quite a bit, 4-Extremely, with lower values representing better outcome. Score for each subscale was normalized to a score ranged from 0 to 100, where higher score=worse symptoms. An overall Lee cGvHD score was calculated as average of these 7 subscales and it ranged from 0 to 100, where a higher score = worse symptoms. EOT visit was performed within 3 days after the participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication.
| score on a scale | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Cycle 2, Day 1 | — | — | -5.2 ± 6.3 |
| Cycle 3, Day 1 | -3.0 ± 8.5 | 0.5 ± 7.3 | -4.3 ± 8.2 |
| Cycle 4, Day 1 | — | — | -2.7 ± 8.2 |
| Cycle 5, Day 1 | -3.7 ± 11.0 | -3.7 ± 7.0 | -0.5 ± 10.8 |
| Cycle 6, Day 1 | — | — | -0.8 ± 9.3 |
| Cycle 7, Day 1 | -4.9 ± 8.4 | -2.2 ± 8.8 | -2.0 ± 12.3 |
| Cycle 8, Day 1 | — | -7.1 ± 10.1 | -2.9 ± 10.9 |
| Cycle 9, Day 1 | -3.7 ± 10.7 | -4.2 ± 5.5 | -3.6 ± 10.2 |
| Cycle 10, Day 1 | — | -2.7 ± 6.1 | -3.7 ± 9.9 |
| Cycle 11, Day 1 | -3.4 ± 11.5 | -5.5 ± 6.0 | -4.5 ± 6.1 |
| Cycle 12, Day 1 | -3.9 ± 8.1 | -7.6 ± 7.7 | -2.8 ± 6.0 |
| Cycle 13, Day 1 | -5.8 ± 14.7 | -5.9 ± 8.8 | -0.6 ± 7.1 |
| Cycle 14, Day 1 | -1.6 ± 17.1 | -5.0 ± 7.3 | -1.5 ± 7.7 |
| Cycle 15, Day 1 | -4.8 ± 15.8 | -6.8 ± 7.0 | -3.2 ± 8.2 |
| Cycle 16, Day 1 | -4.6 ± 16.1 | -6.9 ± 7.6 | 1.9 ± 7.9 |
| Cycle 17, Day 1 | -4.1 ± 17.2 | -10.1 ± 5.5 | 0.0 ± 12.5 |
| Cycle 18, Day 1 | -2.3 ± 17.6 | -11.5 ± 8.4 | -2.3 ± 7.8 |
| Cycle 19, Day 1 | -7.7 ± 19.6 | -9.9 ± 7.8 | -6.6 ± 9.9 |
| Cycle 20, Day 1 | -4.6 ± 22.0 | -9.0 ± 10.3 | -2.8 ± 5.6 |
| Cycle 21, Day 1 | -3.1 ± 19.1 | -7.5 ± 10.7 | -4.0 ± 7.9 |
| Cycle 22, Day 1 | -4.1 ± 18.9 | -14.5 ± 9.1 | -3.6 ± 5.0 |
| Cycle 23, Day 1 | -4.1 ± 19.1 | -11.6 ± 9.3 | -6.2 ± 7.7 |
| Cycle 24, Day 1 | -6.7 ± 21.0 | -18.7 | -5.6 ± 5.7 |
| Cycle 25, Day 1 | 2.2 ± 18.8 | -12.4 ± 8.2 | -8.4 ± 3.4 |
| Cycle 26, Day 1 | 1.3 ± 14.3 | — | 0.2 |
| Cycle 27, Day 1 | -3.5 ± 25.3 | -13.2 ± 6.6 | -6.0 ± 9.6 |
| Cycle 28, Day 1 | 4.4 ± 13.4 | — | 2.6 |
| Cycle 29, Day 1 | -2.8 ± 23.7 | -11.0 ± 7.3 | -3.7 ± 13.0 |
| Cycle 30, Day 1 | 9.0 ± 7.5 | — | — |
| Cycle 31, Day 1 | -4.8 ± 27.9 | -15.6 ± 4.3 | -12.9 |
| Cycle 32, Day 1 | 10.3 ± 6.9 | — | — |
| Cycle 33, Day 1 | 0.5 ± 20.7 | -13.5 ± 9.0 | -12.9 |
| Cycle 34, Day 1 | 13.5 ± 3.6 | — | — |
| Cycle 35, Day 1 | -2.5 ± 23.3 | -11.0 ± 12.4 | -12.9 |
| Cycle 36, Day 1 | 7.5 ± 6.4 | — | — |
| Cycle 37, Day 1 | -5.3 ± 29.0 | -13.6 ± 8.1 | — |
| Cycle 38, Day 1 | 9.1 ± 5.2 | — | — |
| Cycle 39, Day 1 | -6.2 ± 25.9 | -14.3 ± 8.5 | -12.9 |
| Cycle 40, Day 1 | 2.7 | — | — |
| Cycle 41, Day 1 | -25.7 | -19.3 | -12.9 |
| Cycle 42, Day 1 | 4.6 | — | — |
| Cycle 43, Day 1 | -20.4 | -19.9 | -12.9 |
| Cycle 44, Day 1 | 4.3 | — | — |
| Cycle 45, Day 1 | — | — | -12.3 |
| Cycle 46, Day 1 | 4.6 | — | — |
| Cycle 47, Day 1 | -6.8 | -16.8 | -12.9 |
| Cycle 48, Day 1 | 2.4 | — | — |
| Cycle 49, Day 1 | — | -15.4 | -14.3 |
| Cycle 50, Day 1 | 4.5 | — | — |
| Cycle 51, Day 1 | -12.0 | — | -12.9 |
| Cycle 52, Day 1 | 6.0 | — | — |
| Cycle 53, Day 1 | -19.2 | — | — |
| Cycle 54, Day 1 | 4.9 | — | — |
| Cycle 55, Day 1 | -16.8 | — | — |
| Cycle 56, Day 1 | 1.8 | — | — |
| Cycle 57, Day 1 | -17.6 | — | — |
| Cycle 58, Day 1 | 5.4 | — | — |
| Cycle 59, Day 1 | -12.7 | — | — |
| Cycle 60, Day 1 | 4.2 | — | — |
| Cycle 61, Day 1 | -19.3 | — | — |
| Cycle 62, Day 1 | 4.4 | — | — |
| Cycle 63, Day 1 | -18.0 | — | — |
| Cycle 67, Day 1 | -21.9 | — | — |
| EOT | -4.3 ± 11.7 | -2.4 ± 10.9 | 2.5 ± 11.9 |
FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.
| percent predicted FEV1 | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Cycle 2, Day 1 | — | — | -4.8 ± 6.7 |
| Cycle 3, Day 1 | 1.1 ± 4.8 | -1.8 ± 7.1 | -1.5 ± 6.2 |
| Cycle 4, Day 1 | — | — | -0.2 ± 8.4 |
| Cycle 5, Day 1 | -3.3 ± 8.0 | -5.0 ± 6.5 | 0.5 ± 5.9 |
| Cycle 6, Day 1 | — | — | -0.9 ± 6.4 |
| Cycle 7, Day 1 | -3.5 ± 4.6 | -2.6 ± 9.4 | -0.9 ± 11.8 |
| Cycle 8, Day 1 | — | 1.0 | -1.1 ± 8.0 |
| Cycle 9, Day 1 | -1.7 ± 6.8 | -5.9 ± 11.7 | -3.0 ± 11.8 |
| Cycle 10, Day 1 | — | -6.0 ± 8.5 | 2.7 ± 3.9 |
| Cycle 11, Day 1 | -4.3 ± 5.2 | -4.0 ± 8.5 | -4.4 ± 15.8 |
| Cycle 12, Day 1 | -2.0 | -1.0 | 0.3 ± 3.6 |
| Cycle 13, Day 1 | -5.9 ± 9.3 | -2.5 ± 14.7 | -3.5 ± 13.2 |
| Cycle 14, Day 1 | 2.0 | 0.0 | -5.1 ± 9.1 |
| Cycle 15, Day 1 | -6.7 ± 11.7 | -2.3 ± 5.1 | -6.1 ± 12.6 |
| Cycle 16, Day 1 | 2.0 | -8.0 ± 15.6 | -4.5 ± 7.3 |
| Cycle 17, Day 1 | -5.3 ± 9.1 | -6.0 ± 7.2 | -7.9 ± 15.5 |
| Cycle 18, Day 1 | — | -7.5 ± 10.6 | 4.0 ± 6.0 |
| Cycle 19, Day 1 | -5.2 ± 9.9 | -6.3 ± 5.5 | 0.5 ± 8.5 |
| Cycle 20, Day 1 | — | -8.0 ± 7.1 | 4.0 ± 10.4 |
| Cycle 21, Day 1 | -7.4 ± 10.6 | 0.0 | -10.0 ± 19.8 |
| Cycle 22, Day 1 | — | -11.0 ± 1.4 | -6.0 ± 17.0 |
| Cycle 23, Day 1 | -4.3 ± 14.6 | -12.5 ± 4.9 | -4.8 ± 11.2 |
| Cycle 24, Day 1 | 2.0 | -18.0 | -19.0 |
| Cycle 25, Day 1 | -11.0 ± 15.6 | -12.5 ± 3.5 | -5.0 ± 11.4 |
| Cycle 26, Day 1 | 0.0 | — | — |
| Cycle 27, Day 1 | -6.5 ± 13.4 | -17.0 ± 9.9 | -10.0 ± 17.0 |
| Cycle 29, Day 1 | -0.5 ± 9.2 | 17.0 ± 11.3 | 0.0 ± 1.4 |
| Cycle 30, Day 1 | 3.0 | — | — |
| Cycle 31, Day 1 | -3.5 ± 12.0 | -19.5 ± 10.6 | -4.0 |
| Cycle 32, Day 1 | 1.0 | — | — |
| Cycle 33, Day 1 | 5.0 ± 5.7 | -1.0 ± 33.9 | — |
| Cycle 34, Day 1 | 2.0 | — | — |
| Cycle 35, Day 1 | 5.0 ± 0.0 | -2.5 ± 30.4 | -4.0 |
| Cycle 36, Day 1 | 3.0 | — | 5.0 |
| Cycle 37, Day 1 | -1.0 | -22.0 | — |
| Cycle 38, Day 1 | 1.0 | — | — |
| Cycle 39, Day 1 | 10.0 ± 2.8 | -23.0 ± 11.3 | -5.0 |
| Cycle 40, Day 1 | -1.0 | — | — |
| Cycle 41, Day 1 | 15.0 | — | — |
| Cycle 43, Day 1 | 16.0 | -21.0 | -7.0 |
| Cycle 47, Day 1 | 5.0 | — | -5.0 |
| Cycle 48, Day 1 | 3.0 | — | — |
| Cycle 49, Day 1 | 8.0 | — | -2.0 |
| Cycle 51, Day 1 | 8.0 | — | — |
| Cycle 52, Day 1 | 0.0 | — | — |
| Cycle 53, Day 1 | 9.0 | — | — |
| Cycle 54, Day 1 | 4.0 | — | — |
| Cycle 55, Day 1 | 13.0 | — | — |
| Cycle 56, Day 1 | 4.0 | — | — |
| Cycle 57, Day 1 | 13.0 | — | — |
| Cycle 58, Day 1 | 5.0 | — | — |
| Cycle 60, Day 1 | 4.0 | — | — |
| Cycle 61, Day 1 | 10.0 | — | — |
| Cycle 62, Day 1 | 2.0 | — | — |
| Cycle 63, Day 1 | 13.0 | — | — |
| Cycle 67, Day 1 | 14.0 | — | — |
| EOT | -1.4 ± 9.0 | -10.1 ± 15.7 | -7.4 ± 14.9 |
FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.
| percent predicted FVC | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Cycle 2, Day 1 | — | — | -5.5 ± 9.9 |
| Cycle 3, Day 1 | 0.5 ± 3.8 | -2.4 ± 6.0 | -3.0 ± 6.7 |
| Cycle 4, Day 1 | — | — | -0.2 ± 8.6 |
| Cycle 5, Day 1 | -0.5 ± 7.1 | -4.3 ± 5.2 | 1.6 ± 6.3 |
| Cycle 6, Day 1 | — | — | 0.8 ± 9.5 |
| Cycle 7, Day 1 | -2.9 ± 5.2 | -1.3 ± 6.4 | 2.3 ± 9.7 |
| Cycle 8, Day 1 | — | 2.0 | 0.4 ± 8.9 |
| Cycle 9, Day 1 | 0.4 ± 5.1 | -2.9 ± 5.5 | -0.8 ± 9.5 |
| Cycle 10, Day 1 | — | -5.0 ± 8.5 | 4.7 ± 4.9 |
| Cycle 11, Day 1 | -1.1 ± 7.3 | -2.7 ± 5.6 | -4.4 ± 12.0 |
| Cycle 12, Day 1 | 2.0 | 1.0 | 0.7 ± 5.8 |
| Cycle 13, Day 1 | -2.4 ± 7.9 | -3.3 ± 15.4 | -4.9 ± 9.8 |
| Cycle 14, Day 1 | 11.0 | 2.0 | -2.7 ± 7.1 |
| Cycle 15, Day 1 | -3.7 ± 10.4 | -3.3 ± 5.5 | -4.8 ± 11.5 |
| Cycle 16, Day 1 | 16.0 | -6.0 ± 19.8 | -6.5 ± 6.5 |
| Cycle 17, Day 1 | -3.2 ± 6.3 | -3.0 ± 11.8 | -5.6 ± 12.8 |
| Cycle 18, Day 1 | — | -7.5 ± 9.2 | 4.0 ± 4.0 |
| Cycle 19, Day 1 | -2.3 ± 6.8 | -5.3 ± 4.7 | 0.8 ± 5.1 |
| Cycle 20, Day 1 | — | -10.5 ± 2.1 | -2.0 ± 5.6 |
| Cycle 21, Day 1 | -3.2 ± 8.1 | -3.0 | -6.6 ± 17.0 |
| Cycle 22, Day 1 | — | -11.0 ± 0.0 | -6.0 ± 8.5 |
| Cycle 23, Day 1 | 0.0 ± 12.3 | -11.0 ± 2.8 | -1.8 ± 10.6 |
| Cycle 24, Day 1 | 4.0 | -13.0 | -15.0 |
| Cycle 25, Day 1 | -7.0 ± 11.3 | -10.5 ± 3.5 | -1.3 ± 11.7 |
| Cycle 26, Day 1 | 4.0 | — | — |
| Cycle 27, Day 1 | -2.0 ± 4.2 | -18.0 ± 12.7 | -4.0 ± 21.2 |
| Cycle 29, Day 1 | 2.5 ± 4.9 | -11.0 | 6.0 ± 1.4 |
| Cycle 30, Day 1 | 4.0 | — | — |
| Cycle 31, Day 1 | 1.5 ± 3.5 | -15.5 ± 7.8 | -4.0 |
| Cycle 32, Day 1 | 2.0 | — | — |
| Cycle 33, Day 1 | 11.0 ± 0.0 | -17.5 ± 7.8 | — |
| Cycle 34, Day 1 | 6.0 | — | — |
| Cycle 35, Day 1 | 11.0 ± 5.7 | -15.0 ± 11.3 | -3.0 |
| Cycle 36, Day 1 | 5.0 | — | 2.0 |
| Cycle 37, Day 1 | 7.0 | -24.0 | — |
| Cycle 38, Day 1 | 2.0 | — | — |
| Cycle 39, Day 1 | 12.5 ± 0.7 | -20.5 ± 12.0 | -1.0 |
| Cycle 40, Day 1 | 3.0 | — | — |
| Cycle 41, Day 1 | 15.0 | — | — |
| Cycle 43, Day 1 | 17.0 | -18.0 | -4.0 |
| Cycle 47, Day 1 | 5.0 | — | -2.0 |
| Cycle 48, Day 1 | 5.0 | — | — |
| Cycle 49, Day 1 | 6.0 | — | 2.0 |
| Cycle 51, Day 1 | 9.0 | — | — |
| Cycle 52, Day 1 | 3.0 | — | — |
| Cycle 53, Day 1 | 8.0 | — | — |
| Cycle 54, Day 1 | 5.0 | — | — |
| Cycle 55, Day 1 | 13.0 | — | — |
| Cycle 56, Day 1 | 7.0 | — | — |
| Cycle 57, Day 1 | 14.0 | — | — |
| Cycle 58, Day 1 | 7.0 | — | — |
| Cycle 60, Day 1 | 8.0 | — | — |
| Cycle 61, Day 1 | 12.0 | — | — |
| Cycle 62, Day 1 | 5.0 | — | — |
| Cycle 63, Day 1 | 12.0 | — | — |
| Cycle 67, Day 1 | 14.0 | — | — |
| EOT | -2.5 ± 10.3 | -8.4 ± 9.2 | -7.8 ± 14.7 |
DLco is a measurement of the ability of the lungs to transfer gases from the air to the blood. Change from baseline in diffusing capacity of the lung for carbon monoxide (percent predicted hemoglobin level corrected) was reported for this measure. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.
| Percent Predicted HGB Corrected DLco | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Cycle 2, Day 1 | — | — | -5.243 ± 9.830 |
| Cycle 3, Day 1 | 4.545 ± 22.991 | -0.638 ± 7.059 | -3.928 ± 9.492 |
| Cycle 4, Day 1 | — | — | 0.278 ± 9.683 |
| Cycle 5, Day 1 | 4.635 ± 23.989 | -4.462 ± 23.621 | -4.111 ± 9.138 |
| Cycle 6, Day 1 | — | — | -3.143 ± 10.385 |
| Cycle 7, Day 1 | 1.521 ± 19.836 | 6.184 ± 9.436 | -4.275 ± 11.464 |
| Cycle 8, Day 1 | — | 3.554 | -3.787 ± 11.983 |
| Cycle 9, Day 1 | -4.514 ± 7.401 | 2.570 ± 8.902 | -2.540 ± 11.897 |
| Cycle 10, Day 1 | — | 4.343 ± 3.144 | 1.328 ± 8.887 |
| Cycle 11, Day 1 | -0.625 ± 7.262 | 6.582 ± 10.695 | -2.720 ± 10.920 |
| Cycle 12, Day 1 | 0.531 | 4.076 | -1.378 ± 6.364 |
| Cycle 13, Day 1 | -5.548 ± 12.175 | 1.882 ± 7.522 | 2.091 ± 13.290 |
| Cycle 14, Day 1 | 12.916 | 0.358 | 0.309 ± 11.651 |
| Cycle 15, Day 1 | 0.228 ± 15.731 | 1.125 ± 5.927 | -5.309 ± 11.514 |
| Cycle 16, Day 1 | 48.465 | -6.618 ± 15.443 | -6.840 ± 15.053 |
| Cycle 17, Day 1 | -1.018 ± 9.226 | 8.458 ± 6.229 | -10.865 ± 13.346 |
| Cycle 18, Day 1 | — | 15.543 ± 11.753 | -3.174 ± 3.106 |
| Cycle 19, Day 1 | -2.293 ± 5.763 | 1.824 ± 8.539 | -2.020 ± 2.436 |
| Cycle 20, Day 1 | — | -14.692 | -13.517 ± 5.936 |
| Cycle 21, Day 1 | -2.778 ± 8.187 | -10.661 | -12.354 ± 12.800 |
| Cycle 22, Day 1 | — | 3.347 ± 3.560 | -17.222 ± 16.947 |
| Cycle 23, Day 1 | 0.354 ± 1.844 | -15.184 ± 20.181 | -2.219 ± 10.614 |
| Cycle 24, Day 1 | 6.945 | -18.095 | -11.430 |
| Cycle 25, Day 1 | -4.461 ± 19.865 | 6.289 ± 2.469 | -13.392 |
| Cycle 26, Day 1 | 4.715 | — | — |
| Cycle 27, Day 1 | -8.047 ± 24.788 | -9.914 ± 15.387 | -11.154 |
| Cycle 29, Day 1 | -6.701 ± 1.671 | -18.814 ± 24.960 | 8.613 |
| Cycle 31, Day 1 | 2.343 ± 20.988 | -0.800 ± 17.528 | 10.833 |
| Cycle 32, Day 1 | 5.586 | — | — |
| Cycle 33, Day 1 | 9.901 ± 9.954 | -5.962 ± 10.550 | — |
| Cycle 34, Day 1 | 4.863 | — | — |
| Cycle 35, Day 1 | 13.867 ± 1.309 | -0.426 ± 6.677 | 5.088 |
| Cycle 36, Day 1 | 4.166 | — | 10.372 |
| Cycle 37, Day 1 | 9.306 | -19.228 | — |
| Cycle 39, Day 1 | 14.754 ± 0.649 | -6.813 ± 12.810 | 5.902 |
| Cycle 40, Day 1 | 5.586 | — | — |
| Cycle 41, Day 1 | 22.884 | — | — |
| Cycle 43, Day 1 | 15.213 | 8.775 | 16.351 |
| Cycle 47, Day 1 | 9.660 | — | — |
| Cycle 49, Day 1 | -3.599 | — | — |
| Cycle 51, Day 1 | 11.734 | — | — |
| Cycle 53, Day 1 | 10.292 | — | — |
| Cycle 55, Day 1 | 16.550 | — | — |
| Cycle 61, Day 1 | 17.682 | — | — |
| Cycle 62, Day 1 | 4.170 | — | — |
| Cycle 63, Day 1 | 26.215 | — | — |
| Cycle 67, Day 1 | 41.384 | — | — |
| EOT | -1.962 ± 11.426 | 0.985 ± 5.919 | -10.371 ± 14.208 |
TLC is the volume of air in the lungs upon the maximum effort of inspiration. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.
| Percent Predicted TLC | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Cycle 2, Day 1 | — | — | -9.0 ± 13.4 |
| Cycle 3, Day 1 | 1.6 ± 11.9 | 1.9 ± 8.5 | -0.6 ± 14.8 |
| Cycle 4, Day 1 | — | — | 3.3 ± 14.0 |
| Cycle 5, Day 1 | -2.6 ± 16.8 | -7.2 ± 10.5 | -1.7 ± 11.2 |
| Cycle 6, Day 1 | — | — | -4.4 ± 11.6 |
| Cycle 7, Day 1 | -3.7 ± 6.6 | -4.4 ± 6.3 | -2.6 ± 13.4 |
| Cycle 8, Day 1 | — | -5.0 | -0.2 ± 12.9 |
| Cycle 9, Day 1 | -2.9 ± 6.1 | -6.0 ± 8.5 | -0.9 ± 15.8 |
| Cycle 10, Day 1 | — | -18.5 ± 6.4 | 3.6 ± 14.7 |
| Cycle 11, Day 1 | 0.7 ± 4.3 | -5.2 ± 11.2 | -3.0 ± 19.7 |
| Cycle 12, Day 1 | -9.0 | 0.0 | -8.0 ± 14.2 |
| Cycle 13, Day 1 | -0.3 ± 7.1 | -10.3 ± 18.7 | -3.3 ± 17.6 |
| Cycle 14, Day 1 | 23.0 | -7.0 | -5.8 ± 16.5 |
| Cycle 15, Day 1 | -2.8 ± 10.8 | -1.0 ± 5.6 | -7.0 ± 12.0 |
| Cycle 16, Day 1 | -3.0 | -14.0 ± 12.7 | -15.5 ± 9.5 |
| Cycle 17, Day 1 | -3.0 ± 6.2 | -17.0 ± 11.4 | -18.1 ± 15.6 |
| Cycle 18, Day 1 | — | -16.0 ± 8.5 | 0.0 ± 13.9 |
| Cycle 19, Day 1 | -4.6 ± 6.1 | -7.7 ± 10.5 | -7.0 ± 5.4 |
| Cycle 20, Day 1 | — | -9.5 ± 16.3 | -9.3 ± 15.4 |
| Cycle 21, Day 1 | 0.3 ± 9.3 | -18.0 | -14.4 ± 24.0 |
| Cycle 22, Day 1 | — | -18.5 ± 6.4 | -21.0 ± 14.1 |
| Cycle 23, Day 1 | 0.0 ± 8.7 | -21.0 ± 19.8 | -2.8 ± 18.8 |
| Cycle 24, Day 1 | 0.0 | -15.0 | -34.0 |
| Cycle 25, Day 1 | -3.0 ± 7.1 | -19.5 ± 13.4 | -6.3 ± 24.1 |
| Cycle 26, Day 1 | 0.0 | — | — |
| Cycle 27, Day 1 | 5.5 ± 16.3 | -24.0 ± 12.7 | -14.5 ± 24.7 |
| Cycle 29, Day 1 | -1.0 ± 17.0 | -27.5 ± 21.9 | 12.0 ± 14.1 |
| Cycle 30, Day 1 | 7.0 | — | — |
| Cycle 31, Day 1 | 7.5 ± 17.7 | -36.0 | 17.0 |
| Cycle 32, Day 1 | 1.0 | — | — |
| Cycle 33, Day 1 | 14.0 ± 11.3 | -39.0 | — |
| Cycle 34, Day 1 | 2.0 | — | — |
| Cycle 35, Day 1 | 10.5 ± 7.8 | -23.5 ± 16.3 | 13.0 |
| Cycle 36, Day 1 | 6.0 | — | -6.0 |
| Cycle 37, Day 1 | -7.0 | -41.0 | — |
| Cycle 38, Day 1 | 2.0 | — | — |
| Cycle 39, Day 1 | 24.0 ± 28.3 | -30.0 ± 21.2 | 23.0 |
| Cycle 40, Day 1 | 0.0 | — | — |
| Cycle 41, Day 1 | 38.0 | — | — |
| Cycle 43, Day 1 | 33.0 | -16.0 | 21.0 |
| Cycle 47, Day 1 | 19.0 | — | 25.0 |
| Cycle 48, Day 1 | -13.0 | — | — |
| Cycle 49, Day 1 | 5.0 | — | 1.0 |
| Cycle 51, Day 1 | 15.0 | — | — |
| Cycle 52, Day 1 | 1.0 | — | — |
| Cycle 53, Day 1 | 15.0 | — | — |
| Cycle 54, Day 1 | 4.0 | — | — |
| Cycle 55, Day 1 | 29.0 | — | — |
| Cycle 56, Day 1 | 9.0 | — | — |
| Cycle 57, Day 1 | 18.0 | — | — |
| Cycle 58, Day 1 | 5.0 | — | — |
| Cycle 60, Day 1 | -3.0 | — | — |
| Cycle 61, Day 1 | 5.0 | — | — |
| Cycle 62, Day 1 | -1.0 | — | — |
| Cycle 63, Day 1 | 12.0 | — | — |
| Cycle 67, Day 1 | 12.0 | — | — |
| EOT | 5.2 ± 27.5 | -2.4 ± 15.0 | -12.6 ± 20.1 |
RV is the volume of air remaining in the lungs after maximum forceful expiration. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.
| percent predicted RV | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Cycle 2, Day 1 | — | — | -18.0 ± 30.1 |
| Cycle 3, Day 1 | 0.2 ± 22.2 | -4.6 ± 18.8 | 9.0 ± 34.4 |
| Cycle 4, Day 1 | — | — | 17.8 ± 29.0 |
| Cycle 5, Day 1 | 5.2 ± 24.5 | -11.5 ± 26.9 | -3.7 ± 29.8 |
| Cycle 6, Day 1 | — | — | -10.9 ± 37.5 |
| Cycle 7, Day 1 | 4.9 ± 29.1 | -9.9 ± 17.1 | -7.5 ± 33.0 |
| Cycle 8, Day 1 | — | -28.0 | 2.5 ± 39.7 |
| Cycle 9, Day 1 | 6.4 ± 27.4 | -19.9 ± 24.3 | 0.1 ± 35.6 |
| Cycle 10, Day 1 | — | -47.5 ± 0.7 | 1.4 ± 38.2 |
| Cycle 11, Day 1 | 22.1 ± 29.6 | -10.5 ± 28.3 | 5.4 ± 38.0 |
| Cycle 12, Day 1 | -28.0 | -5.0 | -22.2 ± 49.9 |
| Cycle 13, Day 1 | 20.3 ± 19.9 | -27.0 ± 35.6 | 0.3 ± 32.6 |
| Cycle 14, Day 1 | 78.0 | -31.0 | -6.5 ± 36.3 |
| Cycle 15, Day 1 | 20.3 ± 27.4 | -0.7 ± 18.1 | -16.7 ± 22.3 |
| Cycle 16, Day 1 | 0.0 | -36.5 ± 13.4 | -27.5 ± 31.9 |
| Cycle 17, Day 1 | 13.6 ± 27.8 | -47.3 ± 25.1 | -39.1 ± 26.2 |
| Cycle 18, Day 1 | — | -42.0 ± 0.0 | -7.3 ± 33.7 |
| Cycle 19, Day 1 | 5.4 ± 28.7 | -19.7 ± 18.0 | -23.5 ± 18.7 |
| Cycle 20, Day 1 | — | -7.5 ± 37.5 | -22.0 ± 44.3 |
| Cycle 21, Day 1 | 8.3 ± 10.0 | -44.0 | -30.2 ± 51.2 |
| Cycle 22, Day 1 | — | -33.0 ± 19.8 | -41.0 ± 46.7 |
| Cycle 23, Day 1 | 0.3 ± 5.1 | -72.0 | 1.5 ± 44.8 |
| Cycle 24, Day 1 | -4.0 | -17.0 | -78.0 |
| Cycle 25, Day 1 | 1.0 ± 9.9 | -34.0 ± 31.1 | -23.3 ± 56.0 |
| Cycle 26, Day 1 | -3.0 | — | — |
| Cycle 27, Day 1 | 19.5 ± 41.7 | -39.5 ± 20.5 | -41.0 ± 28.3 |
| Cycle 29, Day 1 | -13.0 ± 42.4 | -13.0 | 17.5 ± 40.3 |
| Cycle 30, Day 1 | 21.0 | — | — |
| Cycle 31, Day 1 | 15.0 ± 43.8 | -93.0 | 61.0 |
| Cycle 32, Day 1 | 5.0 | — | — |
| Cycle 33, Day 1 | 14.5 ± 36.1 | -70.0 | — |
| Cycle 34, Day 1 | -1.0 | — | — |
| Cycle 35, Day 1 | 3.5 ± 36.1 | -34.5 ± 33.2 | 47.0 |
| Cycle 36, Day 1 | 17.0 | — | -20.0 |
| Cycle 37, Day 1 | -54.0 | -70.0 | — |
| Cycle 38, Day 1 | 8.0 | — | — |
| Cycle 39, Day 1 | 43.0 ± 89.1 | -43.0 ± 42.4 | 81.0 |
| Cycle 40, Day 1 | -1.0 | — | — |
| Cycle 41, Day 1 | 80.0 | — | — |
| Cycle 43, Day 1 | 58.0 | -26.0 | 75.0 |
| Cycle 47, Day 1 | 42.0 | — | 87.0 |
| Cycle 48, Day 1 | -50.0 | — | — |
| Cycle 49, Day 1 | -14.0 | — | -5.0 |
| Cycle 51, Day 1 | 22.0 | — | — |
| Cycle 52, Day 1 | -4.0 | — | — |
| Cycle 53, Day 1 | 22.0 | — | — |
| Cycle 54, Day 1 | 4.0 | — | — |
| Cycle 55, Day 1 | 53.0 | — | — |
| Cycle 56, Day 1 | 17.0 | — | — |
| Cycle 57, Day 1 | 18.0 | — | — |
| Cycle 58, Day 1 | 4.0 | — | — |
| Cycle 60, Day 1 | -20.0 | — | — |
| Cycle 61, Day 1 | -18.0 | — | — |
| Cycle 62, Day 1 | -8.0 | — | — |
| Cycle 63, Day 1 | 6.0 | — | — |
| Cycle 67, Day 1 | 2.0 | — | — |
| EOT | 6.3 ± 24.3 | 10.6 ± 34.9 | -18.5 ± 32.6 |
Cmax was the maximum observed plasma concentration, obtained by a non-compartmental analysis. Cmax data for Belumosudil and its metabolites KD025m1 and KD025m2 are reported in this outcome measure.
| nanograms per milliliter | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Belumosudil: Cycle 1 Day 1 | 2500 ± 60.1 | 1400 ± 98.5 | 2960 ± 69.7 |
| Belumosudil: Cycle 2 Day 1 | 2020 ± 101 | 1890 ± 120 | 3270 ± 63.0 |
| KD025m1: Cycle 1 Day 1 | 44.4 ± 67.9 | 34.8 ± 58.8 | 63.9 ± 59.4 |
| KD025m1: Cycle 2 Day 1 | 36.2 ± 43.0 | 45.0 ± 38.6 | 55.8 ± 82.1 |
| KD025m2: Cycle 1 Day 1 | 208 ± 93.1 | 99.2 ± 112 | 388 ± 82.3 |
| KD025m2: Cycle 2 Day 1 | 158 ± 150 | 145 ± 147 | 265 ± 154 |
Tmax was defined as time to reach maximum observed plasma concentration, obtained by a non-compartmental analysis. Tmax data for Belumosudil and its metabolites KD025m1 and KD025m2 are reported in this outcome measure.
| hours | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Belumosudil: Cycle 1 Day 1 | 2.12 (0.98 to 5.00) | 3.43 (1.97 to 6.00) | 3.03 (1.85 to 6.00) |
| Belumosudil: Cycle 2 Day 1 | 2.53 (0 to 4.87) | 2.47 (0 to 5.83) | 2.66 (1.00 to 6.02) |
| KD025m1: Cycle 1 Day 1 | 2.50 (1.00 to 3.98) | 1.75 (1.08 to 5.95) | 1.98 (0.90 to 4.95) |
| KD025m1: Cycle 2 Day 1 | 2.98 (1.17 to 3.03) | 2.05 (1.08 to 5.83) | 2.17 (1.00 to 4.03) |
| KD025m2: Cycle 1 Day 1 | 2.82 (1.93 to 5.00) | 3.00 (2.00 to 6.00) | 2.98 (1.85 to 6.00) |
| KD025m2: Cycle 2 Day 1 | 2.98 (0 to 3.93) | 2.00 (1.05 to 5.07) | 3.03 (1.98 to 6.02) |
AUC0-6hr was defined as area under the plasma concentration versus time curve from time 0 to 6 hours post-dose, obtained by a non-compartmental analysis from the concentration-time data. AUC0-6hr data for Belumosudil and its metabolites KD025m1 and KD025m2 are reported in this outcome measure.
| hours*nanograms per milliliter | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD |
|---|---|---|---|
| Belumosudil: Cycle 1 Day 1 | 8350 ± 60.3 | 4960 ± 108 | 11500 ± 97.3 |
| Belumosudil: Cycle 2 Day 1 | 7090 ± 95.9 | 7190 ± 115 | 12000 ± 68.8 |
| KD025m1: Cycle 1 Day 1 | 140 ± 72.3 | 114 ± 60.8 | 216 ± 61.9 |
| KD025m1: Cycle 2 Day 1 | 123 ± 38.2 | 160 ± 31.3 | 178 ± 72.9 |
| KD025m2: Cycle 1 Day 1 | 565 ± 90.8 | 282 ± 125 | 1150 ± 97.1 |
| KD025m2: Cycle 2 Day 1 | 471 ± 145 | 513 ± 122 | 923 ± 144 |
Collected over From first dose of study drug up to 28 days after the last dose of study drug (maximum duration: up to 64.2 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 200 mg QD | 5/17 (29.4%) | 5/17 (29.4%) | 17/17 (100%) |
| Cohort 2 200 mg BID | 5/16 (31.3%) | 6/16 (37.5%) | 16/16 (100%) |
| Cohort 3 400 mg QD | 9/21 (42.9%) | 13/21 (61.9%) | 19/21 (90.5%) |
| Event | Cohort 1 200 mg QD | Cohort 2 200 mg BID | Cohort 3 400 mg QD |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/17 | 1/16 | 3/21 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/17 | 1/16 | 3/21 |
| Influenza like illnessGeneral disorders | 0/17 | 0/16 | 2/21 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/17 | 0/16 | 2/21 |
| Non-cardiac chest painGeneral disorders | 0/17 | 1/16 | 0/21 |
| Chronic graft versus host disease in skinImmune system disorders | 0/17 | 1/16 | 0/21 |
| BacteraemiaInfections and infestations | 0/17 | 1/16 | 0/21 |
| CellulitisInfections and infestations | 0/17 | 1/16 | 0/21 |
| Citrobacter infectionInfections and infestations | 0/17 | 1/16 | 0/21 |
| Stenotrophomonas infectionInfections and infestations | 0/17 | 1/16 | 0/21 |
| Event | Cohort 1 200 mg QD | Cohort 2 200 mg BID | Cohort 3 400 mg QD |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 9/17 | 9/16 | 7/21 |
| FatigueGeneral disorders | 6/17 | 3/16 | 10/21 |
| NauseaGastrointestinal disorders | 6/17 | 4/16 | 9/21 |
| DiarrhoeaGastrointestinal disorders | 6/17 | 5/16 | 7/21 |
| Alanine aminotransferase increasedInvestigations | 6/17 | 3/16 | 2/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/17 | 4/16 | 7/21 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/17 | 5/16 | 6/21 |
| AnaemiaBlood and lymphatic system disorders | 5/17 | 4/16 | 0/21 |
| Aspartate aminotransferase increasedInvestigations | 5/17 | 2/16 | 1/21 |
| HypertensionVascular disorders | 5/17 | 2/16 | 4/21 |
Analysis was performed on modified intent-to-treat (mITT) population which included all participants who received at least 1 dose of study medication.
| Age, Continuous(years) | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD | Total |
|---|---|---|---|---|
| Median | 50.0 (20 to 63) | 55.0 (30 to 75) | 46.0 (25 to 75) | 51.5 (20 to 75) |
| Sex: Female, Male(Participants) | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD | Total |
|---|---|---|---|---|
| Female | 4 | 7 | 9 | 20 |
| Male | 13 | 9 | 12 | 34 |
| Race (NIH/OMB)(Participants) | Cohort 1: Belumosudil 200 mg QD | Cohort 2: Belumosudil 200 mg BID | Cohort 3: Belumosudil 400 mg QD | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 0 | 2 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 2 | 2 |
| White | 15 | 14 | 19 | 48 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2016 to primary completion in May 2022, 67 months.
Results were first posted in Jun 2023, 1 year 1 month after primary completion.
Of 102 phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 87. This study's 67 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belumosudil